Oxycodone modulates VEGFA to inhibit cervical cancer cell migration and angiogenesis

Background: Cervical cancer (CC) is a leading cause of cancer-related deaths among women worldwide, necessitating the development of novel therapeutic strategies. Oxycodone, a semi-synthetic opioid, is primarily known for its analgesic properties but has shown potential anti-cancer effects in various malignancies. However, its impact on cervical cancer cells and the underlying mechanisms remain unclear. Methods: Human cervical cancer cell lines Hela and Siha were treated with varying concentrations of oxycodone (10, 20, 40 μg/mL). Cell proliferation was assessed using Cell Counting Kit-8 (CCK-8) and clonogenic assays. Apoptosis was measured by flow cytometry. Cell migration and angiogenesis were evaluated using wound healing and tube formation assays, respectively. VEGFA expression was analyzed by Western blotting. Results: Oxycodone inhibited the proliferation of cervical cancer cells. It induced apoptosis in cervical cancer cells. Oxycodone suppressed the migration and angiogenesis of cervical cancer cells. Mechanistically, oxycodone regulated vascular endothelial growth factor A (VEGFA) expression, leading to the inhibition of cell migration and angiogenesis. Conclusions: Oxycodone exhibits significant anti-cancer effects on cervical cancer cells by inhibiting proliferation, inducing apoptosis, and suppressing migration and angiogenesis through the regulation of VEGFA expression. These findings suggest that oxycodone has potential as a therapeutic agent for cervical cancer treatment.

Oxycodone; Cervical cancer; Growth; Apoptosis; VEGFA

[1] Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, et al. NCCN Guidelines® insights: cervical cancer, version 1.2024. Journal of the National Comprehensive Cancer Network. 2023; 21: 1224–1233.

[2] Saleh M, Virarkar M, Javadi S, Elsherif SB, de Castro Faria S, Bhosale P. Cervical cancer: 2018 revised international federation of gynecology and obstetrics staging system and the role of imaging. American journal of roentgenology. 2020; 214: 1182–1195.

[3] Rahangdale L, Mungo C, O’Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. The BMJ. 2022; 379: e070115.

[4] Palmer TJ, Kavanagh K, Cuschieri K, Cameron R, Graham C, Wilson A, et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation. Journal of the National Cancer Institute. 2024; 116: 857–865.

[5] Barrett JE, Shekarabi A, Inan S. Oxycodone: a current perspective on its pharmacology, abuse, and pharmacotherapeutic developments. Pharmacological Reviews. 2023; 75: 1062–1118.

[6] Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology. 2006; 104: 570–587.

[7] Lazenby M, Ercolano EA. Pain experiences and self-management strategies among gynecologic cancer patients receiving chemotherapy. Cancer Nursing. 2017; 40: 396–403.

[8] Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 2: basic mechanisms that could shift dose response for analgesia. Journal of Pain and Symptom Management. 2001; 21: 255–264.

[9] Tian M, Jin L, Li R, Zhu S, Ji M, Li W. Comparison of oxycodone and morphine on the proliferation, apoptosis and expression of related molecules in the A549 human lung adenocarcinoma cell line. Experimental and Therapeutic Medicine. 2016; 12: 559–566.

[10] Zhou Q, Ye F, Ye Z, Gao N, Kong Q, Hu X, et al. The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism. PeerJ. 2023; 11: e16601.

[11] Vanderbecq Q, Grégory J, Dana J, Dioguardi Burgio M, Garzelli L, Raynaud L, et al. Improving pain control during transarterial chemoembolization for hepatocellular carcinoma performed under local anesthesia with multimodal analgesia. Diagnostic and Interventional Imaging. 2023; 104: 123–132.

[12] Kristensen ML, Waldstrøm M, Laursen ASD, Eriksen K, Ulrichsen SP, Hatch EE, et al. Cervical intraepithelial neoplasia and fecundability: a prospective cohort study. Human Reproduction. 2024; 39: 1835–1843.

[13] Amboree TL, Paguio J, Sonawane K. HPV vaccine: the key to eliminating cervical cancer inequities. The BMJ. 2024; 385: q996.

[14] Xu Y, Pan S, Jiang W, Xue F, Zhu X. Effects of propofol on the development of cancer in humans. Cell Proliferation. 2020; 53: e12867.

[15] Vassoler FM, Budge KE, Isgate SB, Gildawie KR, Byrnes EM. Neuroplasticity-related genes correlate with individual differences in distinct phases of oxycodone self-administration in male rats. Neuropharmacology. 2024; 254: 109972.

[16] Qin W, Zhang L, Wang X, Liu B, Xu L, Liu L, et al. ABCB1 genetic polymorphisms affect opioid requirement by altering function of the intestinal P-glycoprotein. Biomedicine & Pharmacotherapy. 2024; 176: 116897.

[17] Yang HY, Liu D, Wang YP. Physalin A exerts neuroprotective effects: inhibition of OGD/R-induced cellular pyroptosis and inflammatory responses in nerve cells. Signa Vitae. 2023; 19: 168–174.

[18] Li J, Qi J, Zhang J, Zhang Y, Huang X. Relationships between nine neuropsychiatric disorders and cervical cancer: insights from genetics, causality and shared gene expression patterns. BMC Women’s Health. 2024; 24: 394.

[19] Kalogera E, Nevala WK, Finnes HD, Suman VJ, Schimke JM, Strand CA, et al. A phase I trial of nab-paclitaxel/bevacizumab (AB160) nano-immunoconjugate therapy for gynecologic malignancies. Clinical Cancer Research. 2024; 30: 2623–2635.

[20] Brefel-Courbon C, Harroch E, Marques A, Devos D, Thalamas C, Rousseau V, et al. Oxycodone or higher dose of levodopa for the treatment of parkinsonian central pain: OXYDOPA trial. Movement Disorders. 2024; 39: 1533–1543.

[21] Ji M, Cheng J, Zhang D. Oxycodone protects cardiac microvascular endothelial cells against ischemia/reperfusion injury by binding to Sigma-1 Receptor. Bioengineered. 2022; 13: 9628–9644.

[22] Rahbarian H, Nojavan S, Maghsoudi M, Tabani H. In-tube gel electromembrane extraction: a green strategy for the extraction of narcotic drugs from biological samples. Journal of chromatography A. 2023; 1688: 463714.

[23] Hu N, Yu T, Chen J, Zheng S, Yan H, Duan J. Oxycodone stimulates normal and malignant hematopoietic progenitors via opioid-receptor-independent-β-catenin activation. Biochemical and Biophysical Research Communications. 2020; 533: 1457–1463.